Severe adverse reactions are rare with infusions of infliximab in a community setting
- New York University School of Medicine, NYU Hospital for Joint Diseases, New York, USA
- Correspondence to Yusuf Yazici
246 East 20th Street, New York, NY 10003, USA;
- Published Online First 28 September 2010
In this study, Ducharme and colleagues report on the experience in community infusion centres with patients using infliximab for a variety of indications. As the authors state, randomised clinical trials are not the ideal environment to assess safety,1 2 and ‘real-world’ experience after the drugs are available to use give us a more complete picture for both the efficacy and the safety of any medication. This is a commendable effort that will provide important information for practitioners and patients alike.
In this retrospective chart review study, all infusions over 18 months in selected clinics in Ontario were reviewed. These centres had protocols in place, as they should, for recording the incident and …